Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02465528 · OUTCOME

Percent of Participant Deaths During Treatment and Follow-up

Ceritinib Rare Indications Study in ALK+ Tumors · Source last updated 2019-12-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percent of participants
Interval / dispersion
Not reported
Time frame
Baseline up to approximately 84 weeks

What was measured

Deaths due to any cause during treatment and 30 day follow-up

Analysis population: There were no deaths in the ALCL and IMT arms

Groups in this outcome

Anaplastic Large Cell Lymphoma (ALCL)

Patients with a diagnosis of ALCL histologically or cytologically confirmed to be ALK-positive

Inflammatory Myofibroblastic Tumor (IMT)

Patients diagnosed with IMT with a confirmed translocation involving the ALK gene

Glioblastoma (GBM)

Patients with GBM with a translocation involving the ALK gene

Any Other ALK-positive Tumor

Patients with any other ALK-positive tumor. Patients in this arm included adenocarcinoma (n= 2), sarcoma (1) and other (2).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Anaplastic Large Cell Lymphoma (ALCL)1
Inflammatory Myofibroblastic Tumor (IMT)4
Glioblastoma (GBM)12
Any Other ALK-positive Tumor5

Reported measurements

Source class 1
Values in percent of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Anaplastic Large Cell Lymphoma (ALCL)0.0Not reportedNot reportedNot reportedNot reported
Inflammatory Myofibroblastic Tumor (IMT)0.0Not reportedNot reportedNot reportedNot reported
Glioblastoma (GBM)25.0Not reportedNot reportedNot reportedNot reported
Any Other ALK-positive Tumor20.0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0.0
      2. group Id
        OG001
        value
        0.0
      3. group Id
        OG002
        value
        25.0
      4. group Id
        OG003
        value
        20.0
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    2. group Id
      OG001
      value
      4
    3. group Id
      OG002
      value
      12
    4. group Id
      OG003
      value
      5
    units
    Participants
description
Deaths due to any cause during treatment and 30 day follow-up
groups
  1. description
    Patients with a diagnosis of ALCL histologically or cytologically confirmed to be ALK-positive
    id
    OG000
    title
    Anaplastic Large Cell Lymphoma (ALCL)
  2. description
    Patients diagnosed with IMT with a confirmed translocation involving the ALK gene
    id
    OG001
    title
    Inflammatory Myofibroblastic Tumor (IMT)
  3. description
    Patients with GBM with a translocation involving the ALK gene
    id
    OG002
    title
    Glioblastoma (GBM)
  4. description
    Patients with any other ALK-positive tumor. Patients in this arm included adenocarcinoma (n= 2), sarcoma (1) and other (2).
    id
    OG003
    title
    Any Other ALK-positive Tumor
param Type
NUMBER
population Description
There were no deaths in the ALCL and IMT arms
reporting Status
POSTED
time Frame
Baseline up to approximately 84 weeks
title
Percent of Participant Deaths During Treatment and Follow-up
type
SECONDARY
unit Of Measure
percent of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice